Beximco pharma makes Tk 144.54cr profit in July- September

Business Desk :
Beximco Pharmaceuticals raked in Tk 144.54 crore profit in the July-September quarter of the current financial year of 2022-23.
The profit is down a slightly 1.22 per cent from Tk 146.32 crore it raked in during the same quarter a year earlier.
Thus, the consolidated earnings per share (EPS) were Tk 3.24 in July-September this year against Tk 3.28 during the same quarter in 2021, according to the unaudited financial statements of the pharmaceuticals company.
The consolidated EPS declined because of the decreased EPS of the subsidiary Nuvista Pharma and loss incurred by the other newly acquired subsidiary, Synovia Pharma, said Beximco Pharmaceuticals in a filing on the Dhaka Stock Exchange on Sunday.
The consolidated net operating cash flow per share (NOCFPS) fell to Tk 1.53 in the quarter versus Tk 4.46 reported during the same July-September of 2021, due to an increased working capital investment consequent to the record devaluation of the taka and increased price of materials and higher domestic inflation, said the pharmaceuticals company.